- Home
- ABT vs AMGN Comparison
ABT vs AMGN Comparison
Compare ABT & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABT
- AMGN
- Stock Information
- Founded
- ABT 1888
- AMGN 1980
- Country
- ABT United States
- AMGN United States
- Employees
- ABT N/A
- AMGN N/A
- Industry
- ABT Medical/Dental Instruments
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABT Health Care
- AMGN Health Care
- Exchange
- ABT Nasdaq
- AMGN Nasdaq
- Market Cap
- ABT 177.5B
- AMGN 152.1B
- IPO Year
- ABT N/A
- AMGN N/A
- Fundamental
- Price
- ABT $117.37
- AMGN $278.76
- Analyst Decision
- ABT Buy
- AMGN Buy
- Analyst Count
- ABT 16
- AMGN 22
- Target Price
- ABT $129.25
- AMGN $334.58
- AVG Volume (30 Days)
- ABT 5.1M
- AMGN 2.5M
- Earning Date
- ABT 10-16-2024
- AMGN 10-30-2024
- Dividend Yield
- ABT 1.87%
- AMGN 3.23%
- EPS Growth
- ABT 12.04
- AMGN N/A
- EPS
- ABT 3.29
- AMGN 7.83
- Revenue
- ABT $41,217,000,000.00
- AMGN $32,534,000,000.00
- Revenue This Year
- ABT $5.76
- AMGN $20.06
- Revenue Next Year
- ABT $7.18
- AMGN $3.50
- P/E Ratio
- ABT $35.70
- AMGN $35.59
- Revenue Growth
- ABT 3.15
- AMGN 21.25
- 52 Week Low
- ABT $98.95
- AMGN $260.52
- 52 Week High
- ABT $121.64
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- ABT 55.41
- AMGN 22.11
- Support Level
- ABT $114.43
- AMGN $293.80
- Resistance Level
- ABT $117.84
- AMGN $328.25
- Average True Range (ATR)
- ABT 2.25
- AMGN 8.26
- MACD
- ABT -0.04
- AMGN -4.08
- Stochastic Oscillator
- ABT 57.31
- AMGN 4.26
About ABT Abbott Laboratories
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.